Skip to main content

Aurobindo receives FDA nod for 2 generics

The company obtained approval for bromfenac ophthalmic solution and clobazam oral suspension.

Aurobindo has obtained the Food and Drug Administration’s blessing for bromfenac ophthalmic solution 0.09%.

The medication is the generic of Bausch & Lomb’s Bromday.

It is indicated for postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

[Read more: Aurobindo obtains FDA OK for generic Lioresal]

Bromfenac ophthalmic solution has a market value of roughly  $1.6 million for the 12 months ending February 2022, according to IQVIA.

Aurobindo also has received the FDA’s nod for clobazam oral suspension, 2.5mg/mL.

The product is the generic of Lundbeck’s ONFI.

This medication is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years old and older. 

[Read more: Aurobindo obtains FDA nod for generic Tricor]  

Clobazam oral suspension has a market value of roughly $3.6 million for the 12 months ending January 2022, according to IQVIA.

This ad will auto-close in 10 seconds